LEBWOHL, M.; GOODERHAM, M.; WARREN, R. B.; THAÇI, D.; FOLEY, P.; GOTTLIEB, A. B.; HIPPELI, L.; KISA, R. M.; BANERJEE, S.; GRIFFITHS, C. E. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s239, 2023. DOI: 10.25251/skin.7.supp.239. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/2361. Acesso em: 3 jul. 2024.